These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 20944536)
1. Overactive bladder syndrome: what is the role of evidence of detrusor overactivity in the cystometric study? Vecchioli-Scaldazza C; Grinta R Minerva Urol Nefrol; 2010 Dec; 62(4):355-61. PubMed ID: 20944536 [TBL] [Abstract][Full Text] [Related]
2. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288 [TBL] [Abstract][Full Text] [Related]
3. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. Tanaka Y; Masumori N; Tsukamoto T Int J Urol; 2010 Sep; 17(9):796-800. PubMed ID: 20649825 [TBL] [Abstract][Full Text] [Related]
4. Solifenacin succinate for the treatment of symptoms of overactive bladder. Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299 [TBL] [Abstract][Full Text] [Related]
5. Solifenacin objectively decreases urinary sensation in women with overactive bladder syndrome. Lowenstein L; Kenton K; Mueller ER; Brubaker L; Sabo E; Durazo-Arivzu RA; Fitzgerald MP Int Urol Nephrol; 2012 Apr; 44(2):425-9. PubMed ID: 21993768 [TBL] [Abstract][Full Text] [Related]
6. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. Nitti VW; Rovner ES; Bavendam T BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062 [TBL] [Abstract][Full Text] [Related]
7. Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion. Krebs J; Pannek J Spinal Cord; 2013 Apr; 51(4):306-9. PubMed ID: 23247012 [TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M; BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143 [TBL] [Abstract][Full Text] [Related]
9. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066 [TBL] [Abstract][Full Text] [Related]
10. Pre-operative opening detrusor pressure is predictive of detrusor overactivity following TVT in patients with pre-operative mixed urinary incontinence. Panayi DC; Duckett J; Digesu GA; Camarata M; Basu M; Khullar V Neurourol Urodyn; 2009; 28(1):82-5. PubMed ID: 19089898 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study. Chung JH; Lee JY; Kang DH; Ha US; Lee SH; Ham WS; Cho KS; Han JH; Park J; Yoo TK; Lee SW Neurourol Urodyn; 2012 Sep; 31(7):1175-80. PubMed ID: 22674356 [TBL] [Abstract][Full Text] [Related]
12. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Garely AD; Lucente V; Vapnek J; Smith N Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of overactive urinary bladder with imperative urinary incontinence in women]. Neĭmark AI; Riapolova MV; Mel'nik MA Urologiia; 2010; (2):36-8. PubMed ID: 20967993 [TBL] [Abstract][Full Text] [Related]
14. The impact of tension-free vaginal tape on overactive bladder symptoms in women with stress urinary incontinence: significance of detrusor overactivity. Choe JH; Choo MS; Lee KS J Urol; 2008 Jan; 179(1):214-9. PubMed ID: 18001792 [TBL] [Abstract][Full Text] [Related]
15. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome. Hsiao SM; Lin HH; Kuo HC Neurourol Urodyn; 2014 Mar; 33(3):331-4. PubMed ID: 23494586 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. Metello J; Nogueira B; Torgal M; Colaço J; Vieira A; Gonçalves V; Retto H Int Urogynecol J Pelvic Floor Dysfunct; 2007 Sep; 18(9):1021-5. PubMed ID: 17211528 [TBL] [Abstract][Full Text] [Related]
17. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J; BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175 [TBL] [Abstract][Full Text] [Related]
18. Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape--is it effective? Serati M; Braga A; Sorice P; Siesto G; Salvatore S; Ghezzi F J Urol; 2014 May; 191(5):1322-6. PubMed ID: 24148761 [TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women. Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV Urol Int; 2014; 93(4):470-3. PubMed ID: 25170796 [TBL] [Abstract][Full Text] [Related]
20. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]